The IASLC 2020 World Conference on Lung Cancer offers a tremendous opportunity to market to one of the largest international gatherings of researchers, clinicians and professionals in the field of lung cancer and thoracic oncology.
Opens January 27, 2021, 17:00 SGT
Ends February 12, 2021, 17:00 SGT
Meet our lineup of exhibitors attending WCLC 2020. Click on their logo to learn more about them.
AstraZeneca has a deep-rooted heritage in oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients' lives. By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com
Novartis is reimagining medicine to improve people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at www.novartis.com.
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients. To learn more about Lilly’s commitment to people with cancer, please visit www.LillyOncology.com and www.loxooncology.com.
GSK is focused on maximizing patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.
Cancer takes. Takes away time. Takes away loved ones. At Boehringer Ingelheim we are providing new hope for patients by taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immuno-oncology therapies and intelligent combination approaches to help combat many cancers.
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal.
For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases — as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and YouTube.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Our employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices—the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.
Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
For more information, www.takeda.com.
Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based diagnostic company, focusing on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS®、Super-ARMS®、ddCapture®、and HANDLE® technologies, AmoyDx has a market-leading portfolio of molecular diagnostic assays. Based on multiple technology platforms including PCR, NGS, FISH and IHC, AmoyDx’s core product categories including but not limited to single gene testing kits, multi-gene testing panels, NGS panels and NGS analytical systems. In the past years, more than 20 diagnostic kits have been approved by the Chinese authorities, the NMPA and in Europe (CE mark). In several External Quality Assessment (EQA) programs, including EMQN and PQCC, AmoyDx is the NO. 1 testing kit supplier for years and always achieves the highest accuracy rates.
Nowadays, AmoyDx serves an extensive domestic and international oncology network， reaching over 500 top hospitals in China and over 50 countries worldwide. Every year hundreds of thousands of cancer patients benefit from AmoyDx products and services. As diagnostic partner with AstraZeneca, Amgen, Boehringer-Ingelheim, Johnson & Johnson, Eli Lilly, Illumina, Merck and Pfizer, AmoyDx provides diagnostic products and services for trials of drugs in clinical development and for clinical practice. AmoyDx® ROS1 kit was the first approved companion diagnostic kit for Pfizer's crizotinib by Japanese and South Korean authorities
Our mission is to improve healthcare and patients’ lives with superior & innovative products and services Our vision is to be one of the global leading and most reliable suppliers of quality diagnostic products and services for personalized healthcare. We endeavor to accomplish this mission and vision by: 1. Adhering strictly to manufacturing standards to provide quality products. 2. Maintaining an unsurpassed level of customer experience and satisfaction. 3. Pursuing scientific innovation to provide customers with practical leading-edge technologies and value-added products. 4. Creating a world-class organization that contributes positively to the lives of our employees, our customers, the patients and the scientific community.
Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise at Bayer currently includes six marketed products. Several other compounds are in various stages of clinical development, with the focus on potential first-in-class approaches across the areas of novel oncogenic signaling in combination with an effective biomarker strategy, antibody drug conjugates including a thorium platform and immuno-oncology. An Oncology Strategic Business Unit within the Pharmaceuticals Division of Bayer was established in 2017 to support the accelerated development of new treatment options. The company has also established a broad cooperative research network with healthcare professionals, academic research centers, other pharmaceutical companies and innovative biotech organizations worldwide. Together with these partners, we are fostering an open exchange of ideas to expand Bayer's vision of treatment for cancer patients.
Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We support clinical oncology research with innovative technologies and service through our Thermo Scientific, Applied Biosystems, Invitrogen, Gibco and Ion Torrent brands.
Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent’s expertise and trusted collaboration give them the highest confidence in our solutions. Agilent focuses its expertise on six key markets, where we help our customers achieve their goals:
They are namely: Food, Environmental and Forensics, pharmaceuticals, diagnostics, Chemical and Energy, and Research. In particular for diagnostic sector, Agilent gives doctors a head start in the fight against cancer and other diseases. Our solutions, such as companion diagnostic portfolio, help pathology laboratories deliver fast, accurate information to the doctors, hospitals and medical centers they serve. We help medical professionals make more accurate diagnoses so patients can receive the most effective therapies.
Read about the Agilent products and solutions that serve these markets. Discuss your laboratory needs with an Agilent expert
Biodesix is a leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. We strive to be a trusted partner that the world relies on for diagnostic solutions in lung disease by improving overall patient outcomes and lowering the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures.
Burning Rock Dx specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. With the unique capability and experience in global trials, we are looking for partnerships to advance the field of companion diagnostics in order to achieve better patient outcomes. Burning Rock is the market leader in NGS oncology space in China and offers world class leading assay performance supported by independent FDA led study.
Coreline is an AI-based medical imaging solution company, specialized in Lungs.
For WCLC, we present AVIEW LCS B3, which will cover Big 3 thoracic diseases, Lung Cancer, COPD, and Coronary Artery Calcification from a single dose CT scan with proven acceptance from the National lung cancer screening experience from 2017.
Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs.
In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its LUNAR development programs for recurrence and early detection. Since its launch in 2014, Guardant360 has been ordered by more than 7,000 oncologists and over 60 biopharmaceutical companies. Visit us online at www.guardanthealthamea.com.
NeoGenomics specializes in cancer genetics testing and information services. We provide one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer with >600 tests available in-house including extensive molecular profiling in myeloid disorders and leukemias, cfDNA/RNA assays for biopsy-free evaluation of hematologic cancers, and >20 HemeFISH™ panels. The company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development to meet program objectives and delivery from biomarker discovery through CDx validation and commercialization. Collaborations are welcome.
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields). TTFields is a cancer treatment that destroys tumor cells while sparing healthy tissue.
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future.
For additional information on Spectrum Pharmaceuticals, please visit www.sppirx.com.
Since 2007, Regeneron and Sanofi have collaborated to help people with debilitating and complex conditions that are often difficult to diagnose and treat, using fully-human monoclonal antibodies. Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology.
Dedicated to improving patient outcomes through high-quality medical education
Assured Continuing Education (ACE) Oncology is a full-service, global, independent, medical education provider. We specialize in developing and implementing live, web-based, and on-demand educational programs for clinicians who specialize in oncology and hematology.
Our mission is to provide high-quality, evidence-based, tailored solutions that deliver the most up-to-date medical education and support clinicians in making optimal treatment decisions to improve patients’ outcomes.
ACE has a dedicated team of experienced oncology and hematology professionals, who are committed to providing an unbiased perspective focused on enhancing patient care through meaningful medical education.
Clinical Care Options, LLC is the global leader in the development of innovative enduring, virtual, and live education. Integrating personalization and moderated social media, CCO provides medical and healthcare education and information for the entire healthcare team with the goal of improving patient outcomes. The leadership of CCO has been a pioneer in the creation of continuing education and decision support resources for healthcare professionals both in the United States and around the globe for more than two decades. For more information, visit www.clinicaloptions.com.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.
For more information, please visit roche.com.
International Association for the Study of Lung Cancer (IASLC)
IASLC-CorporateRelations at iaslc.org
Phone: +1 720 598 1951
Fax: +1 720 325 2848
Keep up to date with Conference News & Alerts.